QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
^
EQS-News: Crown NL Bidco B.V. / Schlagwort(e): Fusionen & Übernahmen
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary
all-cash public takeover offer
21.10.2026 / 23:38 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
---------------------------------------------------------------------------
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary
all-cash public takeover offer
* QIAGEN and EQT Private Equity agree on an all-cash public takeover offer
for all outstanding QIAGEN shares at an offer price of EUR46.50 per share,
a premium of 40.3% to the unaffected share price
* Following a comprehensive review of strategic options, QIAGEN's
Supervisory Board and Managing Board fully support the transaction and
agreed to unanimously recommend acceptance of the Takeover Offer
* QIAGEN to be better positioned to deliver on its full potential in a
private setting, while shareholders benefit from an attractive all-cash
premium and certain value
* Closing expected in mid-2027, subject to, inter alia, a minimum
acceptance threshold of 50% of the outstanding share capital plus one
QIAGEN share and customary regulatory clearances
Venlo and Amsterdam, the Netherlands, 21 October 2026 - QIAGEN N.V. (NYSE:
QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") and the EQT
XI fund ("EQT Private Equity") today announced an agreement under which
Crown NL Bidco B.V. (the "Bidder") announced its decision to make an
all-cash voluntary public takeover offer for the acquisition of all
outstanding QIAGEN shares at EUR46.50 per share (the "Takeover Offer").
The Bidder is a holding company indirectly controlled by EQT XI fund with
further indirect participations held by co-investors Luxinva S.A. (a
wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA)), and
CPP Investment Board Europe Inc. (a wholly-owned subsidiary of Canada
Pension Plan Investment Board (CPP Investments)). EQT Private Equity is
managed and controlled by affiliates of EQT AB with registered seat in
Stockholm, Sweden ("EQT").
The Takeover Offer follows a comprehensive review by QIAGEN's Supervisory
Board and Managing Board (together the "QIAGEN Boards") that assessed
QIAGEN's strategic prospects and included discussions with both strategic
and financial parties. The QIAGEN Boards believe the transaction will
provide the best environment for QIAGEN's next growth phase, giving QIAGEN
greater flexibility to invest for the long term under private ownership
while providing shareholders with attractive and certain cash value.
The Bidder will offer QIAGEN shareholders EUR46.50 in cash for each QIAGEN
share (the "Offer Price"), which represents an attractive premium of 40.3%
to the XETRA closing price of EUR33.15 per QIAGEN share on 8 July 2026, the
last trading day prior to the publication of market reports regarding
takeover interest from private equity firms, and 46.9% to the three-month
volume-weighted average price (VWAP) on XETRA of EUR31.66 per QIAGEN share up
to and including 8 July 2026.
The transaction values QIAGEN at approximately EUR10.8 billion in enterprise
value (approximately $12.1 billion at current exchange rates, including
approximately $1.1 billion of net debt).
Strategic review supports proposed transaction and partnership with EQT
Private Equity
The QIAGEN Boards unanimously concluded that the transaction is in the best
interest of QIAGEN and its business, taking into account the interests of
QIAGEN's stakeholders.
Stephen H. Rusckowski, Chairman of the Supervisory Board of QIAGEN, said:
"This transaction offers shareholders compelling value while positioning
QIAGEN for its next phase of development under private ownership. After
considering QIAGEN's stand-alone strategic prospects and the alternatives
available through discussions with strategic and financial parties, we
unanimously concluded that this is the best path forward for QIAGEN, its
shareholders and other stakeholders."
Jonathan M. Pratt, Chief Executive Officer of QIAGEN, said: "Since joining
QIAGEN, I have seen firsthand the quality of our people, technologies and
customer relationships. I also see clear opportunities to build on those
strengths and do more for customers. Under private ownership, we can move
faster and have greater freedom to put resources behind the most attractive
opportunities that align best with our long-term strategy. That can help us
grow the business in line with our priorities and create more opportunities
for our people to innovate, develop their careers and help shape the future
of QIAGEN."
Roland Sackers, Chief Financial Officer of QIAGEN, said: "This agreement
provides our shareholders with an attractive premium while giving QIAGEN a
strong partner that shares our strategic priorities and vision for the
future. With EQT's support and resources, we will strengthen our ability to
pursue new opportunities and expand our capabilities, building on the
excellent foundation our teams have created."
Matteo Thun-Hohenstein, Partner at EQT, said: "QIAGEN is an outstanding
global leader in the life science tools and diagnostics market. We have
closely followed the Company for many years and long admired the
long-standing reputation and positive impact of its products and services,
enabling customers to advance cutting-edge science, improve patient outcomes
and gain valuable insights from biological samples. QIAGEN's management team
and employees have built an exceptional company with a portfolio of highly
attractive products and respected brands, strong market positions and
considerable technical expertise. EQT brings deep sector experience, a
global network and operational capabilities, and we are proud to partner
with QIAGEN's highly talented and capable employees to further invest in
QIAGEN's continued product innovation and growth."
Michael Bauer, Global Co-Head of Healthcare at EQT, said: "This is a
landmark transaction for EQT and a powerful reflection of the deep sector
understanding, investment experience and network of expertise we have built
over the last three decades. QIAGEN sits at the heart of modern life
sciences and diagnostics, and we are thrilled to partner with it. We are
proud to be investing alongside ADIA and CPP Investments, whose long-term
perspective and experience with large-scale transactions make them
outstanding partners."
Long-term ownership to support QIAGEN's strategy
As part of the Business Combination Agreement (the "BCA"), EQT Private
Equity has agreed to support QIAGEN's long-term development, including
commitments relating to QIAGEN's strategy, business, key brands, operational
footprint, R&D activities, employee arrangements, prudent financing and
culture of excellence. Following completion of the transaction, QIAGEN will
continue to operate under the QIAGEN name and brand.
EQT is one of the world's leading active ownership investors, with EUR354
billion in assets under management and a three-decade track record of
developing and future-proofing companies. EQT brings deep healthcare and
life sciences experience, supported by around 100 investment professionals
across 15 countries, with over EUR30bn invested across more than 210 companies
in Healthcare globally. Its current and former portfolio companies include
SPT Labtech, Galderma, Parexel, Aldevron, Dako and HemoCue. These
investments underscore strong sector experience across life sciences that
are complementary to QIAGEN's business focus.
Transaction summary and approvals
The QIAGEN Boards unanimously approved the BCA and support the transaction.
The QIAGEN Boards have carefully considered the Takeover Offer and certain
corporate measures to be implemented after closing of the Takeover Offer
that will enable the Bidder to acquire full ownership of the entire business
of QIAGEN (the "Post-Closing Measures").
Under the terms of and subject to the conditions of the BCA, the QIAGEN
Boards will recommend that QIAGEN shareholders tender their shares into the
Takeover Offer and vote in favor of the resolutions relating to the
Post-Closing Measures and associated governance matters at an Extraordinary
General Meeting to be held during the initial acceptance period (the "EGM").
Their formal recommendation will be published in a position statement after
the Bidder publishes the offer document (the "Offer Document").
The Takeover Offer will be subject to a minimum acceptance threshold of 50%
of the Company's outstanding share capital plus one share, the adoption of
certain resolutions at the EGM, including approval of the Post-Closing
Measures, the adoption of a separate decision by the QIAGEN Boards to
implement the Post-Closing Measures (the "Implementation Decision"), merger
control and foreign investment clearances, and certain further conditions,
which will be set forth in the Offer Document.
The implementation of the Post-Closing Measures will result in the Bidder
acquiring full ownership of the entire business of the Company, and all
shareholders of QIAGEN who have not accepted the Takeover Offer receiving a
cash distribution in an amount per share equal to the Offer Price less
applicable withholding taxes, which may result in a lower net amount being
received than if such shareholders had accepted the Takeover Offer. In
connection with the implementation of the Post-Closing Measures, the
listings of QIAGEN shares on the FSE and the NYSE will be terminated.
Under the BCA, the QIAGEN Boards will take the Implementation Decision if
the Post-Closing Measures have been approved at the EGM by at least 80% of
the votes cast. Otherwise, the QIAGEN Boards may still take the
Implementation Decision if they determine, in accordance with their
fiduciary duties, that proceeding with the transaction, including the
Post-Closing Measures, is in the best interest of QIAGEN, taking into
account the interests of its shareholders and other stakeholders and subject
to the support of a substantial majority of its shareholder base.
In determining whether the transaction has the support of a substantial
majority of its shareholder base and whether the voting results provide a
balanced reflection of the underlying shareholder support, the QIAGEN Boards
may consider, amongst other things, the percentage of votes cast in favor of
the Post-Closing Measures, attendance at the EGM, as well as the number of
votes cast in favor of the Post-Closing Measures by longer-term shareholders
compared to those who acquired shares subsequent to the announcement with
the aim of frustrating the transaction or pursuing event-driven hedge fund
strategies.
Closing of the Takeover Offer is currently expected in mid-2027. If closing
has not occurred within 10 months of the date of this announcement because
required regulatory approvals remain pending, QIAGEN may elect under the BCA
to pay shareholders an interim dividend of up to $0.47 per share. Any such
interim dividend would not be deducted from the Offer Price.
Until closing of the Takeover Offer, QIAGEN will continue to operate as an
independent company under its current management.
Next steps
The Takeover Offer will be made pursuant to the terms and conditions set out
in the Offer Document to be approved by the German Federal Financial
Supervisory Authority ("Bafin"). The Offer Document will be published
following clearance by Bafin, at which point the acceptance period for the
Takeover Offer will commence. On the same date, the Bidder will commence the
Takeover Offer in the United States and file a tender offer statement on
Schedule TO with the U.S. Securities and Exchange Commission ("SEC"). The
Offer Document (in German and a non-binding English translation) and other
information pertaining to the Takeover Offer will be made available in
accordance with the German Securities Acquisition and Takeover Act
(Wertpapiererwerbs-
und Übernahmegesetz - WpÜG) on the Bidder's website at www.eqt-offer.com,
and the Schedule TO and related filings will be available through the SEC's
website at www.sec.gov.
Certainty of funds
EQT Private Equity has obtained committed equity and debt financing
sufficient to fund the offer consideration and related transaction costs.
The transaction is not subject to any financing condition. Morgan Stanley,
Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are acting as
bookrunnners and mandated lead arrangers for the committed debt financing.
Advisors
Moelis & Company LLC and Goldman Sachs Bank Europe SE are serving as
financial advisors to QIAGEN, and Perella Weinberg Partners is serving as
financial advisor to the Supervisory Board. De Brauw Blackstone Westbroek
N.V., Linklaters LLP and Davis Polk & Wardwell LLP are serving as legal
counsel to QIAGEN.
Morgan Stanley & Co. International plc ("Morgan Stanley") and Jefferies LLC
("Jefferies") are serving as lead financial advisors to EQT Private Equity,
and Deutsche Bank is serving as financial advisor. Milbank is serving as
lead legal advisor, with Stibbe and Paul Weiss serving as further legal
advisors. Clifford Chance is serving as legal advisor to ADIA and
Freshfields as legal advisor to CPP Investments.
Contacts
QIAGEN
Public Relations: pr@QIAGEN.com
Investor Relations: ir@QIAGEN.com
EQT
International media: EQT Press Office press@eqtpartners.com
DACH media: Isabel Henninger, Kekst CNC, isabel.henninger@kekstcnc.com, +49
174 9409955
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in
Sample to Insight solutions that enable customers to extract and analyze
molecular information from biological samples containing the building blocks
of life. Our Sample technologies isolate and process DNA, RNA and proteins
from blood, tissue and other materials. Assay technologies prepare these
biomolecules for analysis, while bioinformatics support the interpretation
of complex data to deliver actionable insights. Automation solutions
integrate these steps into streamlined, cost-effective workflows. QIAGEN
serves more than 500,000 customers worldwide in the Life Sciences (academia,
pharmaceutical R&D and industrial applications such as forensics) and
Molecular Diagnostics (clinical healthcare). As of September 30, 2026,
QIAGEN employed about 5,400 people across more than 35 locations. For more
information, visit www.qiagen.com.
About EQT
EQT is a purpose-driven global investment organization focused on active
ownership strategies. With a Nordic heritage and a global mindset, EQT has a
track record of more than three decades of developing companies across
multiple geographies, sectors and strategies. EQT has investment strategies
covering all phases of a business' development, from start-up to maturity.
EQT has EUR354 billion in total assets under management (EUR195 billion in
fee-generating assets under management) as of 30 September 2026, within four
business segments - Private Capital, Infrastructure, Real Estate and
Secondaries.
With its roots in the Wallenberg family's entrepreneurial mindset and
philosophy of long-term ownership, EQT is guided by a set of strong values
and a distinct corporate culture. EQT manages and advises funds and vehicles
that invest across the world with the mission to future-proof companies,
generate attractive returns and make a positive impact with everything EQT
does.
The EQT AB Group comprises EQT AB (publ) and its direct and indirect
subsidiaries, which include general partners and fund managers of EQT funds
as well as entities advising EQT funds. EQT has offices in more than 25
countries across Europe, Asia Pacific, the Americas and the Middle East and
has more than 2,000 employees.
More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram
About ADIA
Established in 1976, the Abu Dhabi Investment Authority ("ADIA") is a
globally-diversified investment institution that prudently invests funds on
behalf of the Government of Abu Dhabi through a strategy focused on
long-term value creation.
For more information:
https://www.adia.ae
For further details, please contact:
Garry Nickson Abu Dhabi Investment Authority
T: +971 2 415 6085 E: Garry.Nickson@adia.ae
About CPP Investments
Canada Pension Plan Investment Board (CPP Investments(TM)) is a professional
investment management organization that manages the Canada Pension Plan Fund
in the best interests of the more than 22 million contributors and
beneficiaries. In order to build diversified portfolios of assets, we make
investments around the world in public equities, private equities, real
estate, infrastructure and fixed income. Headquartered in Toronto, with
offices in Hong Kong, London, Mumbai, New York City, São Paulo and Sydney,
CPP Investments is governed and managed independently of the Canada Pension
Plan and at arm's length from governments. At June 30, 2026, the Fund
totaled C$863.6 billion. For more information, please visit
www.cppinvestments.com or follow us on LinkedIn, Instagram or on X
@CPPInvestments.
For further details, please contact:
Frank Switzer
T: + 1-416-523-8039 E: media@cppib.com
Forward-looking statements
Certain statements contained in this communication may be considered
forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended ("Securities Act"), and Section 21E of
the U.S. Securities Exchange Act of 1934, as amended. These statements can
be identified by the use of forward-looking terminology such as "believe",
"hope", "plan", "intend", "seek", "may", "will", "could", "should", "would",
"expect", "anticipate", "estimate", "continue", "target" or other similar
words. To the extent that any of the statements contained herein relating to
QIAGEN N.V.'s ("QIAGEN") products, timing for launch and development,
marketing and/or regulatory approvals, financial and operational outlook,
growth and expansion, acquisitions, collaborations, markets, strategy or
operating results, including without limitation its expected net sales, net
sales of particular products, net sales in particular geographies, adjusted
net sales, expansion of adjusted operating income margin, returns to
shareholders, progressive dividend payments, product portfolio management,
product launches (including anticipated launches of QIAGEN's sequencing
solutions, testing platforms, panels and systems), leveraging AI technology,
improvements in operating and financial leverage, currency movements against
the U.S. dollar, plans for investment in QIAGEN's portfolio and share
repurchase commitments, QIAGEN's expectations relating to QIAGEN's adjusted
tax rate, debt maturity and repayment, QIAGEN's ability to grow adjusted
earnings per share at a greater rate than sales, QIAGEN's ability to improve
operating efficiencies and maintain disciplined capital allocation, are
forward-looking, such statements are based on current expectations and
assumptions that involve a number of uncertainties and risks. These include,
but are not limited to, risks associated with QIAGEN's dependence on the
development and success of new products; management of growth and expansion
of operations (including the effects of currency fluctuations, tariffs, tax
laws, regulatory processes and supply chain dependencies); variability of
operating results; integration of acquired businesses; changes in
relationships with customers, suppliers and strategic partners; competition;
rapid or unexpected changes in technologies; fluctuations in demand for
QIAGEN's products (including fluctuations due to general economic
conditions, the level and timing of customers' funding, budgets and other
factors, including delays or limits in the amount of reimbursement approvals
or public health funding); QIAGEN's ability to obtain and maintain product
regulatory approvals; difficulties in successfully adapting QIAGEN's
products to integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate and protect
QIAGEN's products from competitors' products; market acceptance of new
products and the integration of acquired technologies and businesses;
actions of governments, global or regional economic developments, including
inflation and changing interest rates, weather or transportation delays,
natural disasters, cyber security breaches, political or public health
crises and the resulting impact on the demand for QIAGEN's products and
other aspects of QIAGEN's business, or other force majeure events;
litigation risk, including patent litigation and product liability; debt
service obligations; volatility in the public trading price of QIAGEN
shares; as well as the possibility that expected benefits related to recent
or pending acquisitions may not materialize as expected; and the other
factors discussed under the heading "Risk Factors" in QIAGEN's most recent
Annual Report on Form 20-F. For further information, please refer to
QIAGEN's filings with the U.S. Securities and Exchange Commission (the
"SEC").
The forward-looking statements in this communication also include statements
relating to the tender offer. Additional important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include risks and uncertainties relating to: the
proposed transaction not being timely completed, if completed at all;
uncertainties as to the number of QIAGEN ordinary shares that will be
tendered in the tender offer; the possibility that competing offers will be
made; the possibility that the conditions to the tender offer may not be
satisfied or waived; the occurrence of any event, change or other
circumstance that could give rise to the termination of the business
combination agreement; the completion of the post-closing measures and
implementation of the financing arrangements contemplated in connection with
the tender offer; the receipt of, and any conditions associated with, any
exemptive or other relief requested from the SEC in connection with the
tender offer; regulatory approvals required for the transaction not being
timely obtained, if obtained at all, or being obtained subject to
conditions; prior to the completion of the transaction, QIAGEN's business
experiencing disruptions due to transaction-related uncertainty or other
factors making it more difficult to maintain relationships with employees,
customers, licensees, other business partners or governmental entities;
difficulty retaining key employees; and the outcome of any legal proceedings
related to the proposed transaction. The forward-looking statements
contained in this communication speak only as of the date of this
communication. Neither the Bidder, EQT Private Equity nor QIAGEN undertakes
any obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise, except to the
extent required by applicable law.
Additional Information and Where to Find it
The tender offer referenced herein has not yet commenced. This communication
is for informational purposes only and is neither an offer to purchase nor a
solicitation of an offer to sell any ordinary shares of QIAGEN or any other
securities, nor is it a substitute for the tender offer materials that the
Bidder will file with the SEC and publish in Germany. The terms and
conditions of the tender offer will be published in, and the offer to
purchase ordinary shares of QIAGEN will be made only pursuant to, the Offer
Document and related offer materials prepared by the Bidder and as approved
by the German Federal Financial Supervisory Authority (Bundesanstalt für
Finanzdienstleistungsaufsicht, "BaFin"). Once the necessary permission from
BaFin has been obtained, the Offer Document and related offer materials will
be published in Germany and also filed with the SEC in a tender offer
statement on Schedule TO at the time the tender offer is commenced. QIAGEN
intends to file a solicitation / recommendation statement on Schedule 14D-9
with the SEC with respect to the tender offer; in addition, QIAGEN will
publish a document combining the recommendation statement pursuant to
Section 27 of the German Securities Acquisition and Takeover Act
(Wertpapiererwerbs-
und Übernahmegesetz - "WpÜG") and the position statement pursuant to Section
18 and Annex G of the Dutch Decree on public offers (Besluit openbare
biedingen Wft). The Offer Document for the tender offer (in German and in
English) containing the detailed terms and conditions of, and other
information relating to, the tender offer will, among other things, be
published on the internet at www.eqt-offer.com.
Acceptance of the tender offer by shareholders that are resident outside
Germany and outside of the United States may be subject to further legal
requirements and/or restrictions. With respect to the acceptance of the
tender offer outside Germany and outside of the United States, no
responsibility is assumed for the compliance with such legal requirements
applicable in the respective jurisdiction.x
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER
OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE
SOLICITATION / RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE
AMENDED FROM TIME TO TIME, AS WELL AS QIAGEN'S RECOMMENDATION STATEMENT
PURSUANT TO SECTION 27 WPÜG AND POSITION STATEMENT PURSUANT TO SECTION 18
AND ANNEX G OF THE DUTCH DECREE ON PUBLIC OFFERS (Besluit openbare biedingen
Wft) WILL CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF
QIAGEN ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME
AVAILABLE BECAUSE THEY, AND NOT THIS DOCUMENT, WILL GOVERN THE TERMS AND
CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION
REGARDING TENDERING THEIR ORDINARY SHARES.
The tender offer materials, including the offer to purchase and the related
letter of transmittal and certain other tender offer documents, and the
solicitation/recommendation statement on Schedule 14D-9 (when they become
available) and other documents filed with the SEC by the Bidder or QIAGEN,
may be obtained free of charge at the SEC's website at www.sec.gov or at the
Bidder's website at www.eqt-offer.com. In addition, the Bidder's tender
offer statement and other documents it will file with the SEC will be
available at www.eqt-offer.com. Furthermore, copies of the Offer Document
will also be available free of charge by contacting the information agent to
be identified in the Offer Document.
Governing Law
The tender offer will be made and implemented under the laws of the Federal
Republic of Germany, in particular the WpÜG, certain applicable provisions
of the laws of the Netherlands and certain applicable provisions of the
securities laws of the United States of America. Any agreement that is
entered into as a result of accepting the tender offer will be exclusively
governed by the laws of the Federal Republic of Germany and is to be
interpreted in accordance with such laws.
Acquisition of Shares Outside the Tender Offer
Each of EQT Private Equity and the Bidder reserves the right, within the
limits of applicable law and subject to any exemptive relief from the SEC,
to directly or indirectly acquire shares in QIAGEN outside of the tender
offer, whether on or off the stock exchange. Any such purchases or
arrangements will be made outside the United States and in compliance with
applicable law and subject to any exemptive relief from the SEC. To the
extent such acquisitions occur, information about them, including the number
of, and the price for, the acquired shares in QIAGEN will be published
without undue delay, if and to the extent required under the applicable
statutory provisions.
Information in respect of EQT XI
Any information in respect of the EQT XI fund ("EQT XI") contained herein
does not constitute an offer to sell, nor a solicitation of an offer to buy,
any security, and may not be used or relied upon in connection with any
offer or solicitation of EQT XI. Any offer or solicitation in respect of EQT
XI will be made only through a confidential private placement memorandum and
related documents which will be furnished to qualified investors on a
confidential basis in accordance with applicable laws and regulations. Any
securities of EQT XI referred to herein have not been and will not be
registered under the Securities Act and may not be offered or sold without
registration thereunder or pursuant to an available exemption therefrom. Any
offering of securities of EQT XI to be made in the United States would have
to be made by means of an offering document that would be obtainable from
the issuer or its agents and would contain detailed information about the
issuer of the securities and its management, as well as financial
information. Any EQT XI securities may not be offered or sold in the United
States absent registration or an exemption from registration.
---------------------------------------------------------------------------
21.10.2026 CET/CEST Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate
News/Finanznachrichten und Pressemitteilungen.
Originalinhalt anzeigen:
https://eqs-news.com/?origin_id=9567e4cd-cd95-11f1-9d22-0a083a71a9ab&lang=de
---------------------------------------------------------------------------
Sprache: Deutsch
Unternehmen: Crown NL Bidco B.V.
Johannes Vermeerplein 9
1071 Amsterdam
Niederlande
EQS News ID: 2419988
Ende der Mitteilung EQS News-Service
---------------------------------------------------------------------------
2419988 21.10.2026 CET/CEST
°
